New-generation diabetes management: Glucose sensor-augmented insulin pump therapy

Expert Review of Medical Devices

Volumn 8, Issue 4, 2011, Pages 449-458

  Cengiz, Eda ^a   Sherr, Jennifer L ^a   Weinzimer, Stuart A ^a   Tamborlane, William V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

artificial pancreas; closed loop; continuous glucose monitors; continuous subcutaneous insulin infusion; diabetes; sensor augmented pump therapy

Indexed keywords

ARTIFICIAL PANCREAS; CLOSED-LOOP; CONTINUOUS GLUCOSE MONITORS; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; SENSOR-AUGMENTED PUMP THERAPY;

GLUCOSE; GLUCOSE SENSORS; PUMPS; SENSORS;

INSULIN;

GLUCOSE; INSULIN;

DIABETES MELLITUS; HUMAN; INFUSION PUMP; INSULIN PUMP; INSULIN TREATMENT; REVIEW; SENSOR;

BIOSENSING TECHNIQUES; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN INFUSION SYSTEMS;

EID: 79960075924     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.11.22     Document Type: Review

References (66)

1. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood Type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-2020: a multicentre prospective registration study. Lancet 373(9680), 2027-2033 (2009).
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
3. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br. Med. J. 1(6107), 204-207 (1978). (Pubitemid 8273420)
4. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N. Engl. J. Med. 300(11), 573-578 (1979). (Pubitemid 9123116)
5. Ahern JA, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr. Diabetes 3(1), 10-15 (2002). (Pubitemid 34618799)
6. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with Type 1 diabetes. Diabetes Care 22(11), 1779-1784 (1999). (Pubitemid 29521861)
7. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 107(2), 351-356 (2001). (Pubitemid 32121252)
8. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with Type 1 diabetes. Diabetes Care 26(4), 1142-1146 (2003). (Pubitemid 36929262)
9. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J. Pediatr. Endocrinol. Metab. 16(3), 393-399 (2003). (Pubitemid 37259125)
10. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes. J. Pediatr. 143(6), 796-801 (2003). (Pubitemid 37510652)
11. Burdick J, Chase HP, Slover RH et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 113(3 Pt 1), e221-e224 (2004).
12. Pankowska E, Skorka A, Szypowska A, Lipka M. Memory of insulin pumps and their record as a source of information about insulin therapy in children and adolescents with Type 1 diabetes. Diabetes Technol. Ther. 7(2), 308-314 (2005). (Pubitemid 40586375)
13. Anhalt H, Bohannon NJ. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol. Ther. 12(Suppl. 1), S51-S58 (2010).
14. Cengiz E, Tamborlane WV. A tale of two compartments: interstitial versus blood glucose monitoring. Diabetes Technol. Ther. 11(Suppl. 1), S11-S16 (2009).
15. Koschinsky T, Heinemann L. Sensors for glucose monitoring: technical and clinical aspects. Diabetes Metab. Res. Rev. 17(2), 113-123 (2001). (Pubitemid 32427959)
16. Aye T, Block J, Buckingham B. Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems. Endocrinol. Metab. Clin. North Am. 39(3), 609-624 (2010).
17. Rebrin K, Sheppard NF Jr, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset. J. Diabetes Sci. Technol. 4(5), 1087-1098 (2010).
18. Gerritsen M, Jansen JA, Kros A et al. Influence of inflammatory cells and serum on the performance of implantable glucose sensors. J. Biomed. Mater. Res. 54(1), 69-75 (2001).
19. Kyrolainen M, Rigsby P, Eddy S, Vadgama P. Bio-/haemocompatibility: implications and outcomes for sensors? Acta Anaesthesiol. Scand. Suppl. 104, 55-60 (1995).
20. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 52(11), 2790-2794 (2003). (Pubitemid 37339709)
21. Mang A, Pill J, Gretz N et al. Biocompatibility of an electrochemical sensor for continuous glucose monitoring in subcutaneous tissue. Diabetes Technol. Ther. 7(1), 163-173 (2005). (Pubitemid 40354586)
22. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol. Ther. 2(3), 461-472 (2000).
23. Wolpert HA. The nuts and bolts of achieving end points with real-time continuous glucose monitoring. Diabetes Care 31(Suppl. 2), S146-S149 (2008).
24. Updike SJ, Hicks GP. The enzyme electrode. Nature 214(5092), 986-988 (1967).
25. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res. Clin. Pract. 46(3), 183-190 (1999).
26. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with Type 1 diabetes. Diabetes Care 24(11), 1858-1862 (2001). (Pubitemid 33716491)
27. Kollman C, Wilson DM, Wysocki T, Tamborlane WV, Beck RW. Limitations of statistical measures of error in assessing the accuracy of continuous glucose sensors. Diabetes Technol. Ther. 7(5), 665-672; discussion 673-664 (2005). (Pubitemid 41572065)
28. Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the Guardian RT continuous glucose monitor in children with Type 1 diabetes. Diabetes Technol. Ther. 10(4), 266-272 (2008).
29. Mastrototaro J, Shin J, Marcus A, Sulur G. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with Type 1 diabetes. Diabetes Technol. Ther. 10(5), 385-390 (2008).
30. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol. Ther. 11(2), 65-72 (2009).
31. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 30(5), 1125-1130 (2007). (Pubitemid 46684636)
32. Wilson DM, Beck RW, Tamborlane WV et al. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with Type 1 diabetes. Diabetes Care 30(1), 59-64 (2007). (Pubitemid 46061293)
33. Bailey T, Zisser H, Chang A. New features and performance of a next-generation SEVEN-day continuous glucose monitoring system with short lag time. Diabetes Technol. Ther. 11(12), 749-755 (2009).
34. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 10(5), 622-628 (1987). (Pubitemid 17158937)
35. Clarke WL, Kovatchev B. Continuous glucose sensors: continuing questions about clinical accuracy. J. Diabetes Sci. Technol. 1(5), 669-675 (2007).
36. Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol. Ther. 10(5), 377-383 (2008).
37. Tamborlane WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N. Engl. J. Med. 359(14), 1464-1476 (2008).
38. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with Type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 29(12), 2730-2732 (2006). (Pubitemid 44912209)
39. OConnell MA, Donath S, ONeal DN et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in Type 1 diabetes: a randomised controlled trial. Diabetologia 52(7), 1250-1257 (2009).
40. Chase HP, Beck RW, Xing D et al. Continuous glucose monitoring in youth with Type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol. Ther. 12(7), 507-515 (2007).
41. Chase HP, Beck R, Tamborlane W et al. A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with Type 1 diabetes. Diabetes Care 28(5), 1101-1106 (2005). (Pubitemid 40616619)
42. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled Type 1 diabetes. Diabetes Care 32(8), 1378-1383 (2009).
43. Hirsch IB, Armstrong D, Bergenstal RM et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol. Ther. 10(4), 232-244; quiz 245-236 (2008).
44. Bergenstal RM, Tamborlane WV, Ahmann A et al. Effectiveness of sensor-augmented insulin-pump therapy in Type 1 diabetes. N. Engl. J. Med. 363(4), 311-320 (2010).
45. Hermanides J, Norgaard K, Bruttomesso D et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet. Med. DOI: 10.1111/j.1464-5491.2011.03256.x (2011) (Epub ahead of print).
46. Kordonouri O, Pankowska E, Rami B et al. Sensor-augmented pump therapy from the diagnosis of childhood Type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 53(12), 2487-2495 (2010).
47. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol. Ther. 12(9), 679-684 (2010).
48. Lindpointner S, Korsatko S, Kohler G et al. Glucose levels at the site of subcutaneous insulin administration and their relationship to plasma levels. Diabetes Care 33(4), 833-838 (2010).
49. Swan KL, Dziura JD, Steil GM et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with Type 1 diabetes receiving insulin pump therapy. Diabetes Care 32(2), 240-244 (2009).
50. Swan KL, Weinzimer SA, Dziura JD et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with Type 1 diabetes. Diabetes Care 31(1), 44-46 (2008).
51. Cengiz E, Tamborlane WV, Sherr J et al. Faster is better: investigating the effect of a novel warming device on the pharmacodynamics of rapid acting insulin in youth with Type 1 diabetes (T1D). International Society of Pediatric and Adolescent Diabetes 2010 Meeting Abstract, (P170), 99 (2010).
52. Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J. Diabetes Sci. Technol. 4(2), 419-428 (2010).
53. Buckingham B, Wilson DM, Lecher T, Hanas R, Kaiserman K, Cameron F. Duration of nocturnal hypoglycemia before seizures. Diabetes Care 31(11), 2110-2112 (2008).
54. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 21(5), 817-821 (1998). (Pubitemid 28487078)
55. Hovorka R, Allen JM, Elleri D et al. Manual closed-loop insulin delivery in children and adolescents with Type 1 diabetes: a Phase 2 randomised crossover trial. Lancet 375(9716), 743-751 (2010).
56. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with Type 1 diabetes using an artificial pancreas. Diabetes Care 31(5), 934-939 (2008).
57. National Diabetes Fact Sheet (2007) www.cdc.gov/diabetes/pubs/pdf/ndfs- 2007.pdf (Last accessed March 2011)
58. FDA summary of safety and effectiveness data for Continuous Subcutaneous Glucose Monitoring System www.fda.gov/ohrms/dockets/dockets/05m0454/05m-0454- aav0001-03- SSED-vol1.pdf (Last accessed June 2011)
59. CoPilot® for FreeStyle Navigator® System www.abbottdiabetescare. com/copilot-for-freestyle-navigator-system.html (Last accessed June 2011)
60. ™ SEVEN® PLUS Software www.dexcom.com/ products/dm3-software#preview (Last accessed January 2011)
61. Medtronic CareLink Therapy Management Software for Diabetes https://carelink.minimed.com (Last accessed January 2011)
62. ™ Announces Joint Development Agreement with Animas Corporation http://investor.shareholder.com/dexcom/releasedetail.cfm? ReleaseID=286182 (Last accessed January 2011)
63. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes www.prnewswire.com/news-releases/jdrf-forms- partnership-with-animas-to-develop-first-generation-automated-system-for- managing-type-1-diabetes-81323767. html (Last accessed December 2010)
64. Feasibility Study to Assess the Safety and Functionality of the GluSense Continuous Glucose Monitor in Diabetic Patients http://clinicaltrials.gov/ct2/ show/NCT01198678 (Last accessed December 2010)
65. ™ www.medtronic-diabetes.co.uk/product- information/paradigm-veo/index.html (Last accessed January 2011)
66. The MiniMed Paradigm® Veo System http://medtronic-diabetes.com.au/ paradigm-veo.html (Last accessed January 2011)